Company
Headquarters: Mountain View, CA, United States
Employees: 166
CEO: Mr. Michael L. Favet
$287.5 Million
USD as of Jan. 1, 2024
Company | Market Cap (USD) |
---|---|
Abbott | $192.67 B |
Stryker Corporation | $113.24 B |
Medtronic | $111.60 B |
Boston Scientific Corporation | $85.22 B |
Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
NeuroPace, Inc. has the following listings and related stock indices.
Stock: NASDAQ: NPCE wb_incandescent